Research Article 
Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
Małgorzata Mysliwiec, Mieczysław Walczak, Ewa Małecka-Tendera, Anna Dobrzanska, Barbara Cybulska, Krzysztof Filipiak, Artur Mazur, Przemysława Jarosz-Chobot, Agnieszka Szadkowska, Andrzej Rynkiewicz, Alicja Chybicka, Piotr Socha, Agnieszka Brandt, Joanna Bautembach-Minkowska, Tomasz Zdrojewski, Janusz Limon, Samuel S. Gidding and Maciej Banach
Journal of Clinical Lipidology, 2014, 8(2), 173-180. DOI: 10.1016/j.jacl.2014.01.001
Abstract
Familial hypercholesterolemia (FH) affects on average 1 in 500 individuals in European countries, and it is estimated that FH in Poland may affect more than 80,000 people. However, in Poland, only about 20% of the population is estimated to have been diagnosed with FH, of which only a small number receive adequate treatment. FH results in more rapid development of atherosclerosis and is associated with a high risk of cardiovascular events. Atherosclerosis develops beginning in childhood in patients with FH and reaches advanced stages before clinical manifestations develop. Inadequate diagnostics and treatment of FH in Polish children suggests a need for raising the level of awareness and understanding of the condition in both society and among health professionals. These recommendations present the current epidemiological status, guidelines for diagnosing FH in Polish children and adolescents, and effective treatment options.
ASCI-ID: 2746-391
Similar Articles
Prevalence of metabolic syndrome and insulin resistance among Egyptian adolescents 10 to 18 years of age
Journal of Clinical Lipidology, 2010, 4(3), 185-195. DOI: 10.1016/j.jacl.2010.03.007
Elevated atherogenic lipoproteins in childhood: Risk, prevention, and treatmentJournal of Clinical Lipidology, 2008, 2(3), 138-146. DOI: 10.1016/j.jacl.2008.04.006
Metabolic syndrome and dyslipidemia in youthJournal of Clinical Lipidology, 2008, 2(3), 147-155. DOI: 10.1016/j.jacl.2008.04.005
Getting the word out: Teaching middle-school children about cardiovascular diseaseJournal of Clinical Lipidology, 2008, 2(3), 179-188. DOI: 10.1016/j.jacl.2008.03.004
Lipids and lipoprotein ratios: Contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitusJournal of Clinical Lipidology, 2013, 7(5), 441-445. DOI: 10.1016/j.jacl.2013.05.002
Non-HDL-cholesterol in an adolescent diabetes populationJournal of Clinical Lipidology, 2014, 8(2), 194-198. DOI: 10.1016/j.jacl.2013.12.006
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?Journal of Clinical Lipidology, 2010, 4(3), 152-155. DOI: 10.1016/j.jacl.2010.03.005
High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal womenJournal of Clinical Lipidology, 2008, 2(4), 298-303. DOI: 1016/j.jacl.2008.06.004
Chronic kidney disease as a cardiovascular risk state and considerations for the use of statinsJournal of Clinical Lipidology, 2008, 2(5), 318-327. DOI: 10.1016/j.jacl.2008.06.008
Population variations in atherogenic dyslipidemia: A report from the HeartSCORE and IndiaSCORE StudiesJournal of Clinical Lipidology, 2008, 2(6), 410-417. DOI: 10.1016/j.jacl.2008.10.005
Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CADJournal of Clinical Lipidology, 2009, 3(1), 45-50. DOI: 10.1016/j.jacl.2008.12.003
Postprandial lipemia as an early predictor of cardiovascular complications in childhood obesityJournal of Clinical Lipidology, 2009, 3(2), 78-84. DOI: 10.1016/j.jacl.2009.02.006
The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical reviewJournal of Clinical Lipidology, 2009, 3(2), 85-93. DOI: 10.1016/j.jacl.2009.01.004
Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering-lipoprotein changes and interactions: the SANDS studyJournal of Clinical Lipidology, 2009, 3(5), 322-331. DOI: 10.1016/j.jacl.2009.09.001
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductionsJournal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016
Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics StudyJournal of Clinical Lipidology, 2010, 4(5), 435-443. DOI: 10.1016/j.jacl.2010.07.007
Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002
Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidologyJournal of Clinical Lipidology, 2011, 5(3), 124-132. DOI: 10.1016/j.jacl.2011.02.006
Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurementJournal of Clinical Lipidology, 2011, 5(4), 264-272. DOI: 10.1016/j.jacl.2011.05.004
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A reviewJournal of Clinical Lipidology, 2012, 6(1), 5-18. DOI: 10.1016/j.jacl.2011.10.018
Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older menJournal of Clinical Lipidology, 2012, 6(1), 58-65. DOI: 10.1016/j.jacl.2011.10.019
Fatty acids in cardiovascular health and disease: A comprehensive updateJournal of Clinical Lipidology, 2012, 6(3), 216-234. DOI: 10.1016/j.jacl.2012.04.077
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein loweringJournal of Clinical Lipidology, 2012, 6(4), 303-309. DOI: 10.1016/j.jacl.2012.05.004
High-density lipoprotein subclasses and their relationship to cardiovascular diseaseJournal of Clinical Lipidology, 2012, 6(6), 496-523. DOI: 10.1016/j.jacl.2012.03.001
Postprandial lipemia is not increased in patients with previous unprovoked venous thromboembolismJournal of Clinical Lipidology, 2013, 7(1), 48-55. DOI: 10.1016/j.jacl.2012.06.001
Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapyJournal of Clinical Lipidology, 2014, 8(1), 18-28. DOI: 10.1016/j.jacl.2013.11.002
Education for lifestyle-based management of hyperlipidemia in children enhanced by a collaborative approachJournal of Clinical Lipidology, 2014, 8(2), 187-193. DOI: 10.1016/j.jacl.2013.12.002
JCL Roundtable: HDL in the primary care settingJournal of Clinical Lipidology, 2014, 8(4), 364-372. DOI: 10.1016/j.jacl.2014.05.009
A pilot study in the efficacy and safety of gemfibrozil in a pediatric populationJournal of Clinical Lipidology, 2008, 2(2), 106-111. DOI: 10.1016/j.jacl.2008.02.003
Elevated atherogenic lipoproteins in childhood: Risk, prevention, and treatmentJournal of Clinical Lipidology, 2008, 2(3), 138-146. DOI: 10.1016/j.jacl.2008.04.006
Metabolic syndrome and dyslipidemia in youthJournal of Clinical Lipidology, 2008, 2(3), 147-155. DOI: 10.1016/j.jacl.2008.04.005
Plasma lipid profile and lipid peroxidation in beta-thalassemic childrenJournal of Clinical Lipidology, 2008, 2(6), 405-409. DOI: 10.1016/j.jacl.2008.10.008
The use of lipid-lowering drugs in childrenJournal of Clinical Lipidology, 2010, 4(6), 449-461. DOI: 10.1016/j.jacl.2010.10.003
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemiaJournal of Clinical Lipidology, 2011, 5(2), 76-81. DOI: 10.1016/j.jacl.2011.01.005
The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery diseaseJournal of Clinical Lipidology, 2012, 6(1), 81-87. DOI: 10.1016/j.jacl.2011.06.017
Paradoxical Relationship Between Reactive Hyperemia Index and Age in Children with Lipid DisordersJournal of Clinical Lipidology, 2012, 6(3), 271-272. DOI: 10.1016/j.jacl.2012.04.043
Screening and management of cardiovascular risk factors in childrenJournal of Clinical Lipidology, 2013, 7(5), 390-398. DOI: 10.1016/j.jacl.2013.02.001
Integrated guidance on the care of familial hypercholesterolemia from the International FH FoundationJournal of Clinical Lipidology, 2014, 8(2), 148-172. DOI: 10.1016/j.jacl.2014.01.002
Pediatric dyslipidemias: Prescription medication efficacy and safetyJournal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008
Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemiaJournal of Clinical Lipidology, 2009, 3(2), 94-100. DOI: 10.1016/j.jacl.2009.02.004
No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statinsJournal of Clinical Lipidology, 2010, 4(4), 288-292. DOI: 10.1016/j.jacl.2010.02.011
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductionsJournal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016
Defining the challenges of FH Screening for familial hypercholesterolemiaJournal of Clinical Lipidology, 2010, 4(5), 338-341. DOI: 10.1016/j.jacl.2010.08.022
Defining the challenges of familial hypercholesterolemia screening: IntroductionJournal of Clinical Lipidology, 2010, 4(5), 342-345. DOI: 10.1016/j.jacl.2010.08.014
Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresisJournal of Clinical Lipidology, 2010, 4(5), 346-349. DOI: 10.1016/j.jacl.2010.08.013
Novel therapies and new targets of treatment for familial hypercholesterolemiaJournal of Clinical Lipidology, 2010, 4(5), 350-356. DOI: 10.1016/j.jacl.2010.08.015
Patient tolerance regarding different low-density lipoprotein apheresis columns: Frequent minor side effects and high patient satisfactionJournal of Clinical Lipidology, 2011, 5(1), 45-49. DOI: 10.1016/j.jacl.2010.11.003
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatinJournal of Clinical Lipidology, 2011, 5(1), 50-56. DOI: 10.1016/j.jacl.2010.11.001
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemiaJournal of Clinical Lipidology, 2011, 5(2), 76-81. DOI: 10.1016/j.jacl.2011.01.005
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patientsJournal of Clinical Lipidology, 2011, 5(3), 133-140. DOI: 10.1016/j.jacl.2011.03.001
Antisense therapy and emerging applications for the management of dyslipidemiaJournal of Clinical Lipidology, 2011, 5(6), 441-449. DOI: 10.1016/j.jacl.2011.08.007
Management of familial hypercholesterolemia during pregnancy: Case series and discussionJournal of Clinical Lipidology, 2012, 6(1), 88-91. DOI: 10.1016/j.jacl.2011.08.005
Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemiaJournal of Clinical Lipidology, 2012, 6(4), 331-339. DOI: 10.1016/j.jacl.2012.03.004
Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemiaJournal of Clinical Lipidology, 2012, 6(6), 585-592. DOI: 10.1016/j.jacl.2012.02.005
Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresisJournal of Clinical Lipidology, 2013, 7(2), 109-116. DOI: 10.1016/j.jacl.2012.08.001
Duplication of exon 7-12 in the low-density lipoprotein receptor gene in three Danish patients with familial hypercholesterolemiaJournal of Clinical Lipidology, 2013, 7(2), 174-177. DOI: 10.1016/j.jacl.2012.11.003
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert ForumJournal of Clinical Lipidology, 2013, 7(3), 217-221. DOI: 10.1016/j.jacl.2013.01.005
JCL Roundtable: Diagnosis of severe familial hypercholesterolemiaJournal of Clinical Lipidology, 2013, 7(6), 540-545. DOI: 10.1016/j.jacl.2013.08.003
Delayed diagnosis of familial hypercholesterolemia: A case report of two patients from EgyptJournal of Clinical Lipidology, 2013, 7(6), 683-688. DOI: 10.1016/j.jacl.2013.08.002
Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapyJournal of Clinical Lipidology, 2014, 8(1), 18-28. DOI: 10.1016/j.jacl.2013.11.002
Integrated guidance on the care of familial hypercholesterolemia from the International FH FoundationJournal of Clinical Lipidology, 2014, 8(2), 148-172. DOI: 10.1016/j.jacl.2014.01.002
Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practiceJournal of Clinical Lipidology, 2014, 8(4), 373-380. DOI: 10.1016/j.jacl.2014.06.002
JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemiaJournal of Clinical Lipidology, 2014, 8(1), 10-17. DOI: 10.1016/j.jacl.2013.09.004
rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemiaJournal of Clinical Lipidology, 2014, 8(4), 418-422. DOI: 10.1016/j.jacl.2014.04.003
The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined HyperlipidemiaJournal of Clinical Lipidology, 2009, 3(3), 167-178. DOI: 10.1016/j.jacl.2009.04.052
Attainment of low-density lipoprotein cholesterol goals in coronary artery diseaseJournal of Clinical Lipidology, 2010, 4(3), 173-180. DOI: 10.1016/j.jacl.2010.03.002
Point: Statins, plant sterol absorption, and increased coronary riskJournal of Clinical Lipidology, 2008, 2(4), 304-305. DOI: 10.1016/j.jacl.2008.06.005
Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertisingJournal of Clinical Lipidology, 2008, 2(1), 51-57. DOI: 10.1016/j.jacl.2008.01.002
Pediatric dyslipidemias: Prescription medication efficacy and safetyJournal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008
Optimal management of lipids in diabetes and metabolic syndromeJournal of Clinical Lipidology, 2008, 2(5), 335-342. DOI: 10.1016/j.jacl.2008.08.444
Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemiaJournal of Clinical Lipidology, 2009, 3(1), 33-38. DOI: 10.1016/j.jacl.2008.12.007
Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoringJournal of Clinical Lipidology, 2009, 3(6), 385-392. DOI: 10.1016/j.jacl.2009.10.004
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductionsJournal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016
Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresisJournal of Clinical Lipidology, 2010, 4(5), 346-349. DOI: 10.1016/j.jacl.2010.08.013
Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progressionJournal of Clinical Lipidology, 2010, 4(5), 365-370. DOI: 10.1016/j.jacl.2010.08.008
Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapyJournal of Clinical Lipidology, 2011, 5(2), 97-104. DOI: 10.1016/j.jacl.2011.01.006
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatinJournal of Clinical Lipidology, 2011, 5(1), 50-56. DOI: 10.1016/j.jacl.2010.11.001
Carotid intima-media thickness for the practicing lipidologistJournal of Clinical Lipidology, 2010, 4(1), 24-35. DOI: 10.1016/j.jacl.2009.11.004
No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statinsJournal of Clinical Lipidology, 2010, 4(4), 288-292. DOI: 10.1016/j.jacl.2010.02.011
Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemiaJournal of Clinical Lipidology, 2011, 5(6), 483-492. DOI: 10.1016/j.jacl.2011.09.001
The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatinJournal of Clinical Lipidology, 2012, 6(1), 42-49. DOI: 10.1016/j.jacl.2011.08.006
Management of familial hypercholesterolemia during pregnancy: Case series and discussionJournal of Clinical Lipidology, 2012, 6(1), 88-91. DOI: 10.1016/j.jacl.2011.08.005
Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin usersJournal of Clinical Lipidology, 2012, 6(3), 208-215. DOI: 10.1016/j.jacl.2012.03.003
Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidenceJournal of Clinical Lipidology, 2012, 6(5), 413-426. DOI: 10.1016/j.jacl.2012.04.003
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsJournal of Clinical Lipidology, 2012, 6(5), 434-442. DOI: 10.1016/j.jacl.2012.04.002
Review of red yeast rice content and current Food and Drug Administration oversightJournal of Clinical Lipidology, 2013, 7(2), 117-122. DOI: 10.1016/j.jacl.2012.09.003
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingJournal of Clinical Lipidology, 2013, 7(5), 399-407. DOI: 10.1016/j.jacl.2013.06.002
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemiaJournal of Clinical Lipidology, 2013, 7(6), 561-565. DOI: 10.1016/j.jacl.2013.10.001
Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemiaJournal of Clinical Lipidology, 2013, 7(5), 408-413. DOI: 10.1016/j.jacl.2013.06.010
Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statinsJournal of Clinical Lipidology, 2012, 6(2), 168-173. DOI: 10.1016/j.jacl.2011.12.008
The high-dose rosuvastatin once weekly study (The HD-ROWS)Journal of Clinical Lipidology, 2012, 6(4), 362-367. DOI: 10.1016/j.jacl.2011.11.002
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full reportJournal of Clinical Lipidology, 2014, 8(1), 29-60. DOI: 10.1016/j.jacl.2013.12.005
Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE studyJournal of Clinical Lipidology, 2014, 8(1), 69-76. DOI: 10.1016/j.jacl.2013.10.006
Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular diseaseJournal of Clinical Lipidology, 2014, 8(1), 107-116. DOI: 10.1016/j.jacl.2013.09.009
Register-based predictors of adherence among new statin users in FinlandJournal of Clinical Lipidology, 2014, 8(1), 117-125. DOI: 10.1016/j.jacl.2013.09.008
Efficacy and Safety of Multi-drug Therapy for HypertriglceridemiaJournal of Clinical Lipidology, 2008, 2(3), 204-205. DOI: 10.1016/j.jacl.2008.04.015
Discontinuation Rate Due to Flushing Is Less than 6% Following Therapy with a Proprietary Niacin Extended-ReleaseJournal of Clinical Lipidology, 2008, 2(3), 210-211. DOI: 10.1016/j.jacl.2008.04.021
Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrantsJournal of Clinical Lipidology, 2013, 7(2), 178-181. DOI: 10.1016/j.jacl.2012.11.002
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert ForumJournal of Clinical Lipidology, 2013, 7(3), 217-221. DOI: 10.1016/j.jacl.2013.01.005
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein loweringJournal of Clinical Lipidology, 2012, 6(4), 303-309. DOI: 10.1016/j.jacl.2012.05.004